Fig. 1: Prevalence of NTRK fusion-positive specimens in FoundationCORE by indication and age group.
From: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
The prevalence of NTRK gene fusions overall and among adult (agedāā„18 years) and paediatric patients (agedā<18 years; (a). The prevalence of NTRK gene fusions by age group (b). The prevalence of NTRK gene fusions by cancer type among: all patients (c), adult patients (d) and paediatric patients (e), with n numbers representing the total number of patients analysed per tumour type. Prevalence analysis of cancer types among all NTRK fusion-positive tumours in adults (f) and paediatric patients (g), where numbers represent the total number of patients with each cancer type. CNS central nervous system, CRC colorectal carcinoma, CUP unknown primary carcinoma, GI gastrointestinal, GIST gastrointestinal stromal tumour, NSCLC non-small cell lung cancer, NTRK neurotrophic tyrosine receptor kinase, PNS peripheral nervous system.
